'We still believe they're the leaders in the GLP-1 drugs': Seigerman on Eli Lilly

Key Concepts

• GLP-1 Drugs: Glucagon-like peptide-1 receptor agonists, used for weight loss and diabetes management (e.g., Zepbound, Wegovy, oral formulations).
• HIV Prevention (Yesgo): Long-acting injectable preventative treatment for HIV.
• Cell Therapy: Treatments utilizing living cells to treat diseases, particularly blood cancers.
• Multiple Myeloma: A cancer of plasma cells.
• Bitterpertinent (DISC Medicine): A drug candidate for a rare blood disorder, granted priority review.
• Myelofibrosis: A rare blood cancer affecting the bone marrow.
• Ventix Bio: A biotech company specializing in small molecule drugs for inflammatory diseases.
• MFN Pricing: Most Favored Nation pricing, a policy aimed at lowering drug costs.
• Priority Review Voucher: Granted by the FDA to incentivize development of drugs for rare diseases or unmet medical needs.
• M&A: Mergers and Acquisitions – consolidation within the pharmaceutical industry.

Gilead Sciences: HIV Leadership and Expansion

Gilead is currently the leading company in HIV treatment and prevention. Evan Seagerman highlighted their bullish outlook on Yesgo, a long-acting injectable prevention asset for HIV. Beyond prevention, Gilead is making significant progress in cell therapy for blood cancers, positioning itself to compete with companies like Johnson & Johnson and Legend Biotech (Carvykti) in the multiple myeloma space. A deal with the Trump administration late last year addressed investor concerns regarding MFN (Most Favored Nation) pricing for their HIV business. Gilead has streamlined its operations, improved its P&L, and is now poised for growth and strong returns through the end of the decade. The continued prevalence of millions of people living with HIV globally, coupled with the focus on preventing new cases, ensures a substantial market for Gilead’s HIV franchise, projected to remain strong into the 2030s.

DISC Medicine: A Biotech with Multiple Opportunities

DISC Medicine (ticker: IRON) is a biotech company focused on blood-related disorders, reflected in its ticker symbol. The company received a Commissioner’s National Priority Review Voucher for its drug candidate, bitterpertinent, which could be approved this month. This voucher incentivizes the rapid review of drugs addressing significant unmet medical needs. Phase 2 data for bitterpertinent was positive. DISC Medicine is also developing a drug for anemia associated with myelofibrosis, a competitive space. Seagerman emphasized DISC Medicine’s strength lies in its “multiple shots on goal” – a diverse pipeline for a small biotech company.

Eli Lilly: Beyond Obesity and Inflammatory Disease Focus

Eli Lilly is a key pick, driven primarily by its leadership in the GLP-1 drug market. Zepbound is considered the best-in-class GLP-1 drug. The anticipated approval of an oral GLP-1 drug, orforglipron, in the first half of 2024 will directly compete with Novo Nordisk’s oral Wegovy. Lilly is expanding beyond obesity, with a portfolio spanning the spectrum of obesity treatments – from lower efficacy options like orforglipron to more potent drugs like retatride for significant weight loss. Crucially, Lilly maintains a diversified business with assets in oncology, neuroscience, and inflammation, providing stability compared to Novo Nordisk’s heavier focus on obesity and diabetes.

Oral GLP-1 Drugs and Semaglutide Generics

The FDA approved Novo Nordisk’s oral semaglutide tablet (WGOI) in late December, with availability starting through a cash-pay channel at $149/month for the low dose. Seagerman also noted reports of potential delays in the approval of a generic semaglutide in Canada due to manufacturing issues. He clarified the correct pronunciation is “semaglutide,” not “semmedlide.”

2024 & 2026 Outlook: Increased M&A Activity

Looking ahead, Seagerman predicts a significant increase in M&A (Mergers and Acquisitions) activity within the pharmaceutical industry. Large pharmaceutical companies like Merck, Bristol Myers Squibb, and Eli Lilly will need to acquire assets to bolster their portfolios, benefiting the smaller biotech ecosystem. This trend is expected to be a key driver of the pharmaceutical space going forward, as highlighted by the potential acquisition of Ventix Bio by Eli Lilly.

Ventix Bio Acquisition: Expanding Lilly’s Inflammatory Disease Pipeline

Eli Lilly is reportedly in talks to acquire Ventix Bio for approximately $1 billion. This acquisition would provide Lilly with a portfolio of small molecule drugs targeting various inflammatory diseases, including ulcerative colitis, Crohn’s disease, and potential applications in the cardiovascular system and Parkinson’s disease. Seagerman characterized this as Lilly buying a “platform and assets” with potential, acknowledging some risk but emphasizing Lilly’s focus on expanding beyond obesity into the inflammatory space.

Logical Connections

The discussion flowed logically from broad market trends (Gilead’s HIV leadership) to specific company opportunities (DISC Medicine’s pipeline) and potential industry shifts (Eli Lilly’s acquisition of Ventix Bio). The conversation consistently linked drug development to market demand and financial performance, highlighting the interplay between scientific innovation and business strategy. The discussion of oral GLP-1 drugs and semaglutide generics served as a timely update on a rapidly evolving area of the pharmaceutical market.

Conclusion

The interview with Evan Seagerman presented a bullish outlook on several pharmaceutical companies, emphasizing the importance of innovation, diversification, and strategic acquisitions. Gilead’s continued dominance in HIV, DISC Medicine’s promising pipeline, and Eli Lilly’s expansion beyond obesity all represent compelling investment opportunities. The anticipated increase in M&A activity suggests a dynamic and potentially lucrative environment for investors in the pharmaceutical sector. The key takeaway is that companies with strong pipelines, diversified portfolios, and the capacity for strategic transactions are best positioned for success in the evolving pharmaceutical landscape.